Moderna (MRNA) to Release Quarterly Earnings on Friday

Moderna (NASDAQ:MRNA) is projected to issue its Q2 2026 results before the market opens on Friday, July 31st. Analysts expect Moderna to announce earnings of ($2.00) per share and revenue of $102.9280 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, July 31, 2026 at 8:00 AM ET.

Moderna (NASDAQ:MRNA) last released its earnings results on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing the consensus estimate of ($3.02) by ($0.38). Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The firm had revenue of $389.00 million during the quarter, compared to analysts’ expectations of $236.37 million. During the same period last year, the business earned ($2.52) earnings per share. The business’s revenue was up 260.2% on a year-over-year basis. On average, analysts expect Moderna to post $-6 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Moderna Stock Down 2.4%

MRNA stock opened at $54.49 on Thursday. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.41 and a quick ratio of 2.35. The firm has a market capitalization of $21.62 billion, a P/E ratio of -6.69 and a beta of 0.94. Moderna has a 52-week low of $22.28 and a 52-week high of $85.60. The company’s 50 day simple moving average is $59.00 and its 200-day simple moving average is $52.33.

Analyst Ratings Changes

Several research firms have weighed in on MRNA. The Goldman Sachs Group lifted their price objective on shares of Moderna from $49.00 to $67.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Moderna in a report on Friday, June 12th. Royal Bank Of Canada raised their target price on Moderna from $38.00 to $45.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. Barclays lifted their price target on Moderna from $25.00 to $48.00 and gave the company an “equal weight” rating in a report on Thursday, April 2nd. Finally, Bank of America upped their price target on Moderna from $34.00 to $38.00 and gave the company an “underperform” rating in a research report on Tuesday, July 7th. Two research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and five have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Moderna has a consensus rating of “Reduce” and a consensus price target of $40.00.

Insider Activity at Moderna

In other Moderna news, Director Noubar Afeyan sold 9,263 shares of Moderna stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $46.84, for a total transaction of $433,878.92. Following the completion of the sale, the director owned 3,924 shares of the company’s stock, valued at $183,800.16. This trade represents a 70.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Shannon Thyme Klinger sold 3,471 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.00, for a total transaction of $173,550.00. Following the transaction, the insider owned 67,468 shares in the company, valued at approximately $3,373,400. This represents a 4.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 125,088 shares of company stock worth $6,193,713 in the last 90 days. 10.80% of the stock is owned by corporate insiders.

Institutional Trading of Moderna

Several hedge funds and other institutional investors have recently modified their holdings of the company. MUFG Securities EMEA plc acquired a new stake in shares of Moderna in the second quarter worth about $28,000. EverSource Wealth Advisors LLC increased its holdings in shares of Moderna by 148.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after acquiring an additional 801 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Moderna in the 4th quarter valued at approximately $47,000. Intesa Sanpaolo S.p.A. bought a new position in shares of Moderna in the 4th quarter valued at approximately $51,000. Finally, Brown Brothers Harriman & Co. lifted its holdings in Moderna by 169.4% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,972 shares of the company’s stock worth $51,000 after purchasing an additional 1,240 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.